Roche, Galaxy Biotech ink antibody license agreement
November 2012

BASEL, Switzerland—Roche has announced, together with Galaxy Biotech LLC, the licensing of exclusive worldwide development and commercialization rights to Galaxy's antibodies targeting fibroblast growth factor 2 for the treatment of cancer. Per the agreement, Roche will pay Galaxy $8 million in a license fee, and Galaxy will also be eligible for certain preclinical, clinical and regulatory development milestone payments, in addition to royalties on sales of resulting products.

"Galaxy's humanized monoclonal antibody to FGF2 has demonstrated considerable promise in preclinical studies, and we look forward to developing this and possibly other derivative compounds to complement Roche's already strong portfolio of antibody products in the oncology field," Mike Burgess, acting head of Roche Pharma Research and Early Development, said in a press release.


1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.